Skip to main content

Alpha-synuclein: Stopping the Sticky Protein behind Parkinson's

November 17, 2016

People with Parkinson's have clumps of the protein alpha-synuclein in brain cells, which researchers believe may lead to disease symptoms and progression. Our panelists discuss clinical trials of therapies to prevent or treat those clumps and protect cells, as well as what we know about this key protein.

Webinar Details


Thursday, November 17, 2016


1 hr


12:00 pm ET

  • MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

    Date of Original Release: November 17, 2016
    Date CME Credit No Longer Available: November 17, 2018

    Learning Objectives

    At the conclusion of this course, participants should be able to:

    1. Summarize what is known about alpha-synuclein and its potential role in Parkinson's disease.
    2. Describe Lewy bodies and their relationship with alpha-synuclein.
    3. Recognize the questions researchers are asking around alpha-synuclein and Lewy bodies.
    4. Discuss therapies that target alpha-synuclein in development for potential disease-modifying effects in Parkinson’s disease.
    5. State why the ability to measure and image alpha-synuclein would advance research; list the approaches to evaluate alpha-synuclein throughout the body.  
    Target Audience

    This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.


    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

    Oakstone Publishing, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.


    Dave Iverson
    No disclosures

    Kuldip Dave, PhD
    Director, Research Programs
    The Michael J. Fox Foundation
    No disclosures

    Patrik Brundin, MD, PhD

    Professor and Director, Center for Neurodegenerative Science
    Van Andel Research Institute
    Advisory Role: AbbVie, Apollo Biologics LP, NeuroDerm
    Board Membership: Renovo Neural, Inc, H.Lundbeck A/S
    Honoraria: AbbVie, Apollo Biologics LP, NeuroDerm, Renovo Neural, Inc, H.Lundbeck A/S
    Ownership Interests: Acousort AB, ParkCell AB
    Patent Copyright License: Co-Inventor of Azilect (Rasagiline)

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.